Clinical trial
A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).
NCT02579863 is registered in ClinicalTrials.gov with Merck Sharp & Dohme LLC as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase III Study of Lenalidomide and Low-Dose Dexamethasone With or Without Pembrolizumab (MK3475) in Newly Diagnosed and Treatment Naïve Multiple Myeloma (KEYNOTE 185).
- Lead sponsor
- Merck Sharp & Dohme LLC
- Phase
- Phase 3
- Overall status
- Terminated
- Start date
- October 19, 2015
- Completion date
- July 13, 2020
- Enrollment
- 310 (actual)
- Sites
- Not reported
Conditions
As the registry lists them; a condition with its own page is linked.